



**The Drug Utilization Review (DUR) Board Reviewed
the Following New Drug Classes on
November 7, 2017**

Dermatologics, Atopic Dermatitis

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Dupixent (Subcutaneous) Injection*.

Movement Disorder Drug Therapy

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Ingrezza (Oral) Capsule*.

Antivirals, Hepatitis C Direct-Acting Agents

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Mavyret (Oral) Tablet*.

Gastrointestinal Agents, Chronic Idiopathic Constipation (CIC)

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Trulance (Oral) Tablet*.

Postmenopausal Osteoporosis, Parathyroid Hormone

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Tymlos (Subcutaneous) Injection*.

Bronchodilators, Anticholinergics

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Utibron (Inhalation) Powder*. The DUR Board also recommended *Non-Preferred* status with *Prior Authorization* for *Combivent (Inhalation) Solution*.